Kevin Feeley has more than 20 years of finance and accounting leadership experience in the healthcare, pharmaceutical, and diagnostics sectors. As Chief Financial Officer at GeneDx, Kevin leads financial strategy, management, and planning. Kevin is also responsible for key operational aspects of the company, including lab network operations, supply chain, and genetic counseling services.
Previously, Kevin served as Chief Financial Officer of OPKO Health’s rapidly growing diagnostics division for six years, which included BioReference Laboratories, Inc. and GeneDx. During the COVID-19 pandemic, Kevin led the operational design and execution of BioReference’s sports diagnostic program serving all four major sports leagues in the U.S.
Before that, Kevin was U.S. Controller at Reckitt Benckiser, a global consumer packaged goods company focused on health, hygiene, and nutrition brands. He also previously led SEC reporting at Bausch Health Companies, a public specialty pharmaceutical company, and spent twelve years in the audit practice of KPMG LLP working closely with large multinational pharmaceutical companies.
Kevin is a Certified Public Accountant and holds a BBA in Accounting from James Madison University.
What is Kevin Feeley's net worth?
The estimated net worth of Kevin Feeley is at least $4.25 million as of September 9th, 2026. Mr. Feeley owns 41,476 shares of GeneDx stock worth more than $4,252,908 as of September 17th. This net worth approximation does not reflect any other assets that Mr. Feeley may own. Learn More about Kevin Feeley's net worth.
How do I contact Kevin Feeley?
Has Kevin Feeley been buying or selling shares of GeneDx?
During the last ninety days, Kevin Feeley has sold $108,222.70 in shares of GeneDx stock. Most recently, Kevin Feeley sold 1,285 shares of the business's stock in a transaction on Wednesday, September 9th. The shares were sold at an average price of $84.22, for a transaction totalling $108,222.70. Following the completion of the sale, the chief financial officer now directly owns 41,476 shares of the company's stock, valued at $3,493,108.72. Learn More on Kevin Feeley's trading history.
Who are GeneDx's active insiders?
GeneDx's insider roster includes Shawn Assad (CAO), Daniel Clark (General Counsel), James Coffin (COO), Bryan Dechairo (COO), Kevin Feeley (CFO), Keith Meister (Director), Richard Pfenniger, Jr. (Director), Richard Pfenniger, Jr. (Director), Anthony Prentice (Insider), Isaac Ro (CFO), Joshua Ruch (Director), Jason Ryan (Chairman of the Board), Eric Schadt (CEO), and Katherine Stueland (CEO). Learn More on GeneDx's active insiders.
Are insiders buying or selling shares of GeneDx?
In the last year, GeneDx insiders bought shares 13 times. They purchased a total of 2,425,941 shares worth more than $106,603,951.31. In the last year, insiders at the sold shares 24 times. They sold a total of 199,647 shares worth more than $19,300,348.96. The most recent insider tranaction occured on September, 9th when CEO
Katherine Stueland sold 3,692 shares worth more than $310,940.24. Insiders at GeneDx own 25.2% of the company.
Learn More about insider trades at GeneDx. Information on this page was last updated on 9/9/2026.
